CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CLINICAL AND EXPERIMENTAL IMMUNOLOGY is published by Wiley-Blackwell Publishing Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune Cell Function and Interaction, T-cell and B-cell Immunology and Immune Response and Inflammation, together about 36.4% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)

Since 1966, Clinical & Experimental Immunology has published research at the forefront of translational and clinical immunology. We remain committed to studies that have the potential to transform the understanding of the immunopathology of human disease and influence both preclinical and clinical practice. We welcome original research that provides mechanistic insights, whether through novel experimental findings, careful confirmation of previously published results, or incremental advances that clarify and extend existing knowledge. We support robust, reproducible science, including confirmation studies enriched with additional data, that plays a crucial role in building a reliable foundation for clinical translation. We are especially interested in manuscripts that: Identify and dissect molecular, cellular, or systemic mechanisms in immune function and dysfunction. Provide well-designed experimental models or clinical investigations that advance our understanding of disease pathways. Offer incremental but meaningful advances that address gaps, resolve inconsistencies, or refine existing hypotheses. Integrate mechanistic findings with translational implications for diagnostics, prognostics, or therapeutics. The journal embraces a broad range of approaches, from the application of state-of-the-art technologies, such as next-generation sequencing, metagenomics, and high-dimensional phenotyping, to innovative experimental or clinical designs that elucidate the mechanisms underlying disease processes, therapeutic responses, or trial outcomes. Journal articles are assessed by our dedicated Section Editors, and our shared editorial vision is to be a trusted venue for robust, reproducible, and mechanistically informative research, where both groundbreaking breakthroughs and careful, incremental progress are valued for their contribution to the foundation upon which clinical advances are built. Manuscripts that do not fit into one of the sections described below will be assessed by our Editor-in-Chief. All papers with high relevance to translational immunology are welcome. Clinical & Experimental Immunology is part of the British Society for Immunology family of journals, including our sibling journals Immunotherapy Advances and Discovery Immunology.

From the journal's Aims & Scope

Research area (LetPub): Immunology

Editor-in-chief Claudia MauriPublisher website

Editorial board by country: 1 in mainland China (about 4%); most named United Kingdom 9, United States 3, Netherlands 3, Canada 2, Australia 2 (23 members with a country) Editorial board ↗Publisher website · 2026-09-30

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

MEDLINEPMCPubMedEmbaseCASCAB AbstractsCurrent ContentsPublisher website

Other: EBSCO, ProQuest, AGRICOLA

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

3.86LetPub · 2026-09-13

Impact factor (publisher) 2025

4.2Publisher website · 2026-09-30

5-year impact factor (publisher) 2025

7.5Publisher website · 2026-09-30

CiteScore 2026-06

7.5LetPub · 2026-09-13

CiteScore (publisher) 2025

7.5Publisher website · 2026-09-30

SJR 2026-06

1.41LetPub · 2026-09-13

SNIP 2026-06

1LetPub · 2026-09-13

h-index

125LetPub · 2026-09-13

h-index

194OpenAlex · 2026-10-01

i10-index

7,561OpenAlex · 2026-10-01

2-year mean citedness

4.19OpenAlex · 2026-10-01

Self-citation rate

2.6%LetPub · 2026-09-13

Share of gold OA articles

39.08%LetPub · 2026-09-13

Volume

Articles per year

82LetPub · 2026-09-13

Downloads per year (publisher) 2025

361,999Publisher website · 2026-09-30

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

3–8 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Submission to first decision 2025

8 daysPublisher website · 2026-09-30

Submission to final decision 2025

8 daysPublisher website · 2026-09-30

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Publisher

Wiley-Blackwell Publishing Ltd

Country or region

ENGLAND

Language

English

Frequency

Monthly

Founded

1966

ISSN

0009-9104

Electronic ISSN

1365-2249

Society / sponsor

British Society for Immunology

Latest issue on the website

Volume 220, Issue 1 (2026)

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website